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Abstract
Background: Internationally, systematic screening for sight-threatening diabetic retinopathy (STDR) usually includes
annual recall. Researchers and policy-makers support extending screening intervals, citing evidence from
observational studies with low incidence rates. However, there is little research around the acceptability to people
with diabetes (PWD) and health care professionals (HCP) about changing eye screening intervals.
Methods: We conducted a qualitative study to explore issues surrounding acceptability and the barriers and
enablers for changing from annual screening, using in-depth, semistructured interviews analysed using the constant
comparative method. PWD were recruited from general practices and HCP from eye screening networks and
related specialties in North West England using purposive sampling. Interviews were conducted prior to the
commencement of and during a randomised controlled trial (RCT) comparing fixed annual with variable (6, 12 or
24 month) interval risk-based screening.
Results: Thirty PWD and 21 HCP participants were interviewed prior to and 30 PWD during the parallel RCT. The
data suggests that a move to variable screening intervals was generally acceptable in principle, though highlighted
significant concerns and challenges to successful implementation. The current annual interval was recognised as
unsustainable against a backdrop of increasing diabetes prevalence. There were important caveats attached to
acceptability and a need for clear safeguards around: the safety and reliability of calculating screening intervals,
capturing all PWD, referral into screening of PWD with diabetic changes regardless of planned interval. For PWD the
6-month interval was perceived positively as medical reassurance, and the 12-month seen as usual treatment.
Concerns were expressed by many HCP and PWD that a 2-year interval was too lengthy and was risky for detecting
STDR. There were also concerns about a negative effect upon PWD care and increasing non-attendance rates.
Amongst PWD, there was considerable conflation and misunderstanding about different eye-related appointments
within the health care system.
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Conclusions: Implementing variable-interval screening into clinical practice is generally acceptable to PWD and
HCP with important caveats, and misconceptions must be addressed. Clear safeguards against increasing non-
attendance, loss of diabetes control and alternative referral pathways are required. For risk calculation systems to be
safe, reliable monitoring and clear communication is required.
Keyword: Qualitative, diabetic retinopathy screening, acceptability
Introduction
The rising prevalence of diabetes over the past 30 years
presents challenging health impacts and costs to individ-
uals, health care systems and wider society. Prevalence
rates in the UK rose from 3.2 million people in 2013 to
4.7 million in 2019, and they are expected to rise to 5.5
million by 2030 [1, 2]. Prevalence rates are increasing
more rapidly in low and middle income countries [3].
Having diabetes can involve a number of related health
issues, including diabetic retinopathy (DR). DR is a
major cause of vision impairment among adults world-
wide and is the second most important cause of visual
loss in England and Wales [4].
In the UK, the National Health Service (NHS) eye
screening programmes have offered annual screening to
all people with diabetes (PWD) over the age of 12 years
for around 10 years. These programmes aim to detect
sight threatening diabetic retinopathy (STDR) before it
affects a person’s sight and when timely, effective treat-
ment can be provided. Evidence suggests that it may be
safe to screen low-risk people at longer intervals [5–11]
and the interval has been extended in some countries
[12, 13]. However, this evidence is not conclusive and is
based largely on modelling rather than experimental re-
search. In those countries, such as the Netherlands,
Iceland, and the city of Hong Kong, with extended inter-
vals the population being covered is significantly differ-
ent to the UK. The shift towards varying screening
intervals is not restricted to DR. For breast cancer there
are moves to identify risk-stratified screening strategies
to lower the rates of over diagnosis and to prevent
deaths [14]. Such directions illustrate a general move
within medicine to personalised health care and poten-
tially to re-allocate resources to those most in need; in
the case of DR screening focusing on non-attenders. Risk
estimating equations have been developed to allow this
personalisation in DR [15–17] and in other specialties
[14, 18]. Nevertheless, there has been little work on the
impact on PWD of changing eye screening intervals and
concern amongst HCP about safety including reduced
attendance and loss of diabetes control [9].
An intervention, such as changing eye screening inter-
vals, can be considered to be implementing evidence-
based practice. The aims of an intervention are to
promote the uptake and optimal use of effective clinical
services, along with modifications to health-related be-
haviour. It can be anticipated that there may be negative
as well as positive outcomes from an intervention, there-
fore effective development and implementation is essen-
tial. Understanding enablers and barriers to change and
then putting in place effective strategies to encourage or
mitigate against their effect is crucial. Models of behav-
iour change can be a useful theoretical lens to explore
behaviour and how to effect positive change. Such
models have been used extensively within clinical and
public health arenas to understand illness and health-
seeking behaviours [19–21]. There have been moves
away from a deficit model, where primarily patients are
perceived as lacking in their understanding and simply
needing “more education” about their condition to re-
solve any issues. The Behaviour Change Wheel (BCW) is
cognisant of the many components involved in changing
health related behaviours, it recognises that the sources
for behaviour can be found within three areas and use-
fully applied to changing eye screening intervals: capabil-
ity (is the individual able to attend eye screening?);
opportunity (does the eye screening service make it as
easy as possible to attend an appointment?); and motiv-
ation (can an individual manage any changes to their eye
screening appointment?) [22]. The BCW approach also
offers screening service commissioners and providers a
range of interventions and policy approaches to align
with PWD and HCP capability, opportunity and motiv-
ation to change eye screening intervals. The BCW has
been successfully used in a number of other clinical
arenas [23, 24].
As part of the ISDR randomised controlled trial (RCT)
[25], we undertook a qualitative study with PWD and
HCP designed to investigate and uncover enablers of
and barriers to behaviour change of moving from annual
to personalised risk-based variable-interval screening
and to gain wider insights into perceptions amongst
PWD and HCP. Our aims were to develop detailed un-
derstandings of the acceptability and enablers for, suc-
cessful implementation of personalised screening in
England and other countries with similar systems. We
followed Medical Research Council (MRC) guidance on
developing and evaluating complex interventions [26].
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Methods
Setting
A programme of applied research developed an en-
hancement to screening for STDR by introducing and
testing an individualised or personalised approach based
on measured patient-centred risk. A novel intervention
was developed comprising variable-interval screening de-
termined by a risk calculation engine (RCE) informed by
real-time demographic, retinal and clinical data from the
individual, referenced to local historical data. Intervals
were allocated at 6, 12 or 24 months for high, medium
or low risk respectively and recalculated at each screen-
ing appointment. A RCT was designed to compare the
efficacy and cost-effectiveness of this individualised
approach to standard fixed interval screening [25]. A
public involvement (PI) group was embedded in the
programme. This setting allowed, for the first time, the
real rather than theoretical investigation of the enablers
and barriers around implementation of varying intervals,
and the use of a risk calculator, in a population from an
established screening programme and in a geographical
location where annual fixed interval screening is already
established.
Design
Semi-structured interviews [27, 28] were conducted to
gather views on risk-based variable-interval screening.
Interviews with PWD were conducted prior to its imple-
mentation (Phase 1, baseline) in the setting of the paral-
lel RCT and subsequently with a second group (Phase 2)
during the RCT. All interviews with HCP took place
prior to implementation.
The research team and the PPI group created inter-
view topic guides. With PWD these covered understand-
ing about diabetes, self-management, health services
contact, responsibility for monitoring diabetes, links be-
tween diabetes and eye health and screening intervals.
With HCP the guides focussed on diabetes services,
current eye screening, future changes to eye screening
and DNA rates. All participants received a brief overview
of the individualised risk-based variable-interval screen-
ing intervention. Most patient interviews were con-
ducted in participants’ homes, though some chose to
complete them in the researcher’s university office, and
one participant completed their interview in their own
work office. HCP were interviewed at their place of
work. Interviews lasted between 30 to 90 min, with most
lasting around 45min.
Participants
PWD aged over 16 years attending the eye screening
programme were identified in two General Practices in a
city in the North West of England. Suitability for partici-
pation was confirmed by a General Practitioner prior to
a letter of invitation and patient information pack with
reply slip being posted out. PWD who were interested in
participating returned the reply slip or contacted the re-
search team to make arrangements for an interview.
Sixty PWD were recruited, 30 to phase 1 (baseline)
and 30 to phase 2 (post implementation of risk-based
variable-interval screening). Thirty-four of the 60 were
men and 8 had type 1 diabetes. The age range was 19–
83. Times since diagnosis were: 1–5 years n = 10, 6–10
years n = 7, 11–15 years n = 4 years, > 15 years n = 9;
range 1–40 years. For phase 2, participant allocation to
risk based screening intervals was: 6 months n = 4, 12
months n = 5, 24 months n = 21.
PWD participants reported a range of social situations;
the occupations described by the sample were very
mixed, including a range of professionals as well as
students and manual workers, retired and unemployed
as well as one person who was unable to work due to
long-term ill health.
HCP were identified by personal and professional local
networks of the research team. To help with time
commitments HCP could participate in individual inter-
views, in groups, or by completing an open-ended ques-
tionnaire to be returned by email. Interviews were
conducted at the HCP’ place of work in a private office
(one joint interview was completed at a participant’s
home). Most interviews lasted around 40 min. Six of the
HCP participants were interviewed as three colleague
pairs.
Twenty-one HCP were recruited. Sixteen participated
in interviews whilst five elected to complete question-
naires via email. Professional roles were: screener/grader
n = 7, consultant ophthalmologist (retina specialist) n =
5, eye screening service manager n = 4, optometrist pro-
viding DR screening n = 2, public health specialist n = 2,
general practitioner n = 1.
Analysis
Interviews were audio-recorded and transcribed verba-
tim to enable detailed analysis. Semi-structured case
summaries were produced by a researcher upon comple-
tion of each interview to provide a summary of key
themes to enable identification of emerging themes to
inform further data collection and analysis. After reading
and re-reading the transcripts, data were analysed to
identify sections of text that informed understandings of
the issues [29–31]. Each concept was assigned a descrip-
tive or analytical code, which was then combined into
conceptual categories and broader themes. Each of the
datasets were coded using NViVO software, which en-
abled searching and retrieval of specific data.
When key themes were identified, a number of charts
were created, based upon the thematic analysis, to en-
able comparison of the datasets, taking a framework
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approach [32, 33]. Data from individual participants
were entered into cells within the chart to enable
comparison on each theme at the level of individual
participant and whether they were a PWD or an HCP.
PI
Our PI group contributed to the research questions and
topic guides, informed analyses and further exploration,
and one member joined the authorship.
Ethics
The two phases of the study were conducted under the
following research ethics committee approvals: 13/NW/
0287 and 16/NW/0061.
Results
Analysis of interviews with PWD and HCP identified
several themes related to changing screening intervals:
the acceptability of changing screening intervals in con-
junction with conditions and safeguards attached to 6,
12 and 24month screening intervals; the safety of the
RCE; and the macro impact of changing screening
intervals.
Acceptability of changing screening intervals
The majority of PWDs in both Phase 1 and 2 expressed
the view that risk-based variable screening intervals were
potentially acceptable. The views of PWD included the
concepts of pragmatism and diverting any cost savings
towards other PWD who may need to be seen more
often.
You know if they don’t need them every year then
yes, why do them every year. And so I would rely on
the practitioner to make the best judgement. (David
PWD, Phase 1)
Yes, you know because if your eyes are not going to
go any worse it is saving money and time isn’t it,
where, they can’t fit everybody in can they….it saves
all that money and so it gives other people a chance
of getting seen doesn’t it? So, I agree with that.
(Susan PWD, Phase 2)
For HCP, the majority were also in favour of introdu-
cing risk-based variable screening intervals.
I think it will be fantastic because as you say there
are lots of patients that you can quite happily review
in 2 years, or 18 months 2 years, so I think that
would be a definite benefit. (Sally HCP)
I don’t have any objections, as long as it is evidence
based you know if there is evidence for it being 24
months, then I am fine. If there is evidence for a
particular group being 10 years, you know if that
what the evidence shows, I am very much things
have to be supported by evidence. (Andrew HCP)
However, implementing such changes to eye screening
was accompanied by a range of caveats which are dis-
cussed in relation to the 6, 12 and 24month screening
interval. The norm is currently 12 months, so we explore
the other options in some detail below, as for some
PWD this is more frequent than currently, for others no
change, and for many, twice as long.
Acceptability of 6month screening interval
Within the variable screening model, allocation to a 6
month interval meant that a PWD was considered to be
at high risk of developing STDR. However, for some
PWD participants, this rationale was not fully under-
stood, with the shorter screening interval interpreted as
a security for checking eyes, with the longer screening
interval of 24 months unwelcome as it was seen as too
prolonged a time to be without eye screening. Addition-
ally, some PWD viewed screening as a preventive meas-
ure in developing DR.
Well, early detection is better for the treatment you
know what I mean, if you find something drastically
wrong with your sight, and they can repair it, a lot,
and if they find it earlier, they could repair it.
(Arthur PWD, Phase 2)
Some PWDs, notably in the 55 plus age range, wanted
to be screened every 6 months, or even every 3 months,
and this related to a belief that they were more suscep-
tible to developing eye disease related to diabetes and
consequently needed to be monitored more often.
When you’re over a sort of certain age like say 60
that’s when things start going downhill - 60. I’m not
saying like everybody - everyone’s different, aren’t they
- but the way I look at it is that I think it should be
every six months ... if you’re a type 1 diabetic you
should have it every three months ... over a certain age
every six months. (George PWD, Phase 2)
For HCP, the 6month interval was welcomed unequivo-
cally as a safeguard for high risk patients, and it was
stressed that this would have to be clearly communi-
cated to PWD.
I do like the idea of the medium risk, sorry the high
risk ones coming back every 6 months… so I do think
that that would be a good thing to have that as a
standard if they were high risk, bring them back in
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the 6 months I think that would be good. (Sarah
HCP)
…and there certainly are patients who need more
closer care, which can’t always be determined just by
looking at a picture of their eye ball essentially. You
know they may be patients in certain ethnic groups,
erm… and certain combinations might, I don’t know,
but it might be for example Asian ladies from I am
just talking off the top of my head, from a Pakistani
origin for example, might it might be part of their so-
cietal erm… nature to not necessarily come to atten-
tion as much. (Andrew HCP)
As evidenced above, there are some tensions within
PWDs’ understandings about the 6 month screening
interval, with it being seen as clinical surveillance which
was a reassurance, against the clinical reality that being
allocated to this interval means that there is a high risk
of developing STDR. Additionally, there was conflation
about the purpose of eye screening, where it was com-
monly perceived to be a preventive measure against DR.
For HCP, the shorter interval was welcomed to monitor
high risk patients.
Acceptability of a 12month screening interval with
conditions
As the eye screening service has been in place for over
10 years in England and Wales, it was perhaps unsurpris-
ing that some PWD felt that annual screening was ac-
ceptable and should remain in place. This was often
related to participants’ positive experiences of attending
eye screening. Any changes made to their screening
interval was felt by some PWD to be up to their HCP to
decide upon, as shown below.
I am quite happy with that. Some people may need
close screening but I am quite happy with the 12
months. If they wanted to see me more frequent or
less frequent, I would just go along with it. (Sheena
PWD, Phase 1)
The reliance upon HCP to decide which interval to allo-
cate a PWD was mentioned by several of the partici-
pants. For other PWD, the annual eye screening
appointment was mistakenly perceived as a reassurance
and safety net for any changes in the eyes during this
time period, illustrating the misunderstanding of the re-
lationship between diabetic health, DR and screening.
I’d rather be seen every 12 months to be honest. I think
people should be seen even if they’re classed as very
low risk. I think even within a year a lot can change.
You can suddenly have a bout of you know, I don’t
know if having a bout of problems with your sugars
would affect your eyes but yes, I just think every 12
months it should be. (Joanne PWD Phase 1)
Whilst some reported feeling reassured by annual
screening, there were misunderstandings about the im-
pact of diabetic health upon eye health and the role of
screening. As the current annual screening interval is
established and embedded into practice, it was foresee-
able that PWD felt that this was an appropriate length of
time for their eye screening. However, discussions also
highlighted misunderstandings about the purpose of eye
screening, as a preventive measure against the develop-
ment of DR, and related to diabetic control.
Acceptability of 24 month screening interval with
conditions
Extending screening intervals to 24 months provoked
the most reaction and responses amongst PWD. The
range of views included an unequivocal rejection of a 2
year interval as illustrated below.
No way! (Melanie PWD Phase 2)
Other PWD were more nuanced in their responses with
concerns about this interval being too long a time period
to go without being seen within the eye screening
programme.
It’s an awful long time, 24 months, isn’t it? (Jean
PWD Phase 1)
There were allied concerns about this interval around
the potential for changes to the eye over 2 years and not
being screened.
I feel like leaving something for two years can be very
risky, because someone could always, all of a sudden
be in a low risk and then take a turn for the worst
and have like their eyes get really bad, really quickly
due to something else. I feel like six and 12 months
is good but then I don’t think 24 months is good, I
think it’s too long because you wouldn’t leave some-
one who had diabetes for two years and not check
their HbA1c, so why would you do it for their eyes?
(Polly PWD Phase 2)
For other PWDs, being assigned to the 2-year screening
interval was a positive reflection of their diabetes
control.
I thought well if I don’t need it doing every 12
months then good, send it to two years. And I didn’t
think anything bad about it. I suppose I was quite
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positive about it really. I thought it was working in
my favour if it was going to last two years ... not
having another appointment to go to ... I always
think, if they extend your visits it means you’re on a
level playing field you know, things are going
smoothly; that’s the way I look at it. (Mary PWD,
Phase 2)
For HCP, the move to 2-year intervals was welcomed as
they highlighted that with annual screening they have to
screen very large numbers of negative patients in order
to identify a screen positive patient and that this seems
like an inefficient approach.
I think looking to change the intervals makes sense
to me a lot because an awful lot of the screening we
do is, there is nothing there. And, even the ones who
have mild background retinopathy you see little or
no progression over several years…And you are see-
ing an awful [lot] of patients who are either having
no retinopathy whatsoever or very, very mild retinop-
athy. (Gerard HCP)
For HCP, extending the screening interval would enable
the better targeting of resources and would benefit pa-
tients who, for example are difficult to engage and often
do not attend for screening, or who are at higher risk of
developing STDR.
Unless we have the resources to follow all these
patients [non-attenders] up, which if we do go to
two-years screening we probably would. (Frankie
HCP)
Similarly to PWD, HCP were concerned about extending
screening intervals for the potential negative impact
upon patient behaviour, namely it would affect risk
perception around eye screening attendance. HCP antic-
ipated that some patients would interpret extended
intervals to mean that eye screening is considered not
essential and there would be a concomitant effect upon
an increase in non-attendance.
If you give someone a two-year appointment, they
are probably thinking, well it can’t be that import-
ant if I don’t have to come back for two years. (Sami
& Suzanne HCP)
Some HCP drew upon their clinical experiences to
support an argument about their unease on extending
screening intervals being at odds with their embedded
narrative to PWD of needing to be screened annually
and related to the trust and relationship between PWD
and HCP.
I just don’t agree with it. We have spent, well I have
spent the last 11 years drumming it into patients
how important it is to be screened every 12 months,
and now this is just going against everything I have
been saying. And 12 months is a long time, and
serious, serious damage can happen in them 12
months, even if they have had nothing in the past, I
have seen it so many times. So I just don’t think it is
worth the risk of moving a patient to 24 months.
(Judith HCP)
There was a concern that PWDs’ trust in the eye screen-
ing services would be undermined by any changes to
screening intervals along with the potential development
of DR. In light of previous comments about the embed-
ded nature of the current annual screening programme
for PWD, any changes were thought to require careful
communication and management.
Additionally, with a potential increase in non-
attendance, there were concerns about the length of
time a patient would go without being seen in the
screening service and the possible impact upon a patient
developing DR and the related costs to the NHS.
What would happen if they DNA if we went onto
the two-yearly intervals and they DNAd that two-
yearly one? It would be four years then. And that
would be more expense wouldn’t it towards the
NHS, I think that would cost more because we would
have more things going wrong. (Janine & Hannah
HCP)
For PWD and HCP, there were a range of responses to
extending screening intervals to 2 years. For some PWD,
an extension was welcome as it reflected good diabetes
self-care, contrasted with outright rejection for others
over concerns about developing eye disease in the
extended time period. For HCP, 2-year intervals were
acceptable in the context of many patients having
minimal or no disease. However, there was some appre-
hension about the perceptual impact upon patients of
changing screening intervals, with PWD feeling that
screening was not as important if changed to a 2-year
interval.
Safety of the risk calculation engine (RCE)
Many of our participants (both PWD and HCP) indi-
cated that they would be supportive of the introduction
of risk-based allocation to variable screening intervals,
on the condition or expectation of particular safeguards
or service enhancements being introduced. For HCP,
their concerns were focused on the safety of the RCE,
specifically, around the quality and availability of data
from different areas of health care services (primary and
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secondary care in the UK) into the RCE and any subse-
quent allocations into a screening interval being made
with incomplete or missing patient data:
One of my concerns would be getting the right
information about the patient from the GPs, from
hospitals. (Sandy & Liz HCP)
This issue of information quality and access was men-
tioned only briefly by a small number of PWD partici-
pants, as might be anticipated given their limited
exposure to NHS information systems.
My only slight concern would be how up to date
would the information in the (risk) engine 1 if you
like would be, in terms of making that decision. And
would it be an annual decision that the software
made? (Kevin PWD, Phase 2)
As illustrated above, understanding when the RCE
would calculate a PWD screening interval was seen as
important. The ISDR RCE calculates the screening
interval every time a PWD attends an eye screening
appointment; PWD in low and medium risk groups
who do not attend are assigned to 12 months for
their next invitation and those in the high risk group
to 6 months. Some HCP were concerned that the in-
creased complexity of the RCE and subsequent
screening allocation could create increased RISK for
patients, implying that the mix of data and systems
could result in incorrect calculations of risk and allo-
cation to the wrong screening interval.
It is a more complex system, more complex recipe so
there may be more opportunities for it to go wrong."
(John HCP)
The risk engine uses five unconnected data record sys-
tems extracted from primary and secondary care, and
the screening programme, all with different administra-
tive teams and access/governance arrangements. Data
are screened and cleaned through bespoke processing.
Risk is then calculated by a chain Markov model using 6
covariates [15].
PWD had similar questions to HCP around the
decision-making involved in allocation to screening in-
tervals. They specifically asked about the process of the
RCE and how it is constructed.
Who decides your risks? That’s what I’d like to know.
(Arthur PWD, Phase 2)
In addition, PWD and HCP wanted to be able to self-
refer, or refer patients back into annual screening if their
‘risk-factors’ changed between extended screening inter-
vals, as explained below
I would feel more confident if there were
safeguards where I can say, well the nurse can
say, oh this is a bit erratic, we will need recourse
to the testing place and see if we can get you a
quicker appointment… ... in theory if everything
stays the same there is no problem with me
having the test every three years… so long as there
are contingencies in place. If I was confident
about safeguards I would be quite happy. (Derek
PWD, Phase 1)
There were calls from PWD for assurances that the re-
call system would need to mitigate against any diabetic
changes which would warrant an earlier recall to eye
screening.
In theory, I would be all right as long as my reading
stayed the same. So I suppose if my readings went
high, and my sugar levels went high, I could say to
the nurse well ok, I've got to have my eyes done now
... If my sugar levels go up for some reason, and I
can’t control them you know, I could have my eyes
done. (Jane PWD, Phase 2)
Similarly, HCP wanted assurances that the risk engine
would be robust in identifying and inviting all PWD to
be screened. Whilst recognising that the RCE was com-
plex and sophisticated, HCP stressed there had to be ob-
vious checks and balances of the system, rather than
relying on computers and software.
There should be some kind of backup where at least
there is somebody in the real world who is actually
ensuring that things have not gone really haywire.
(Sami & Suzanne HCP)
A further safety concern on extending screening inter-
vals was the potential of missing STDR and the subse-
quent risk of patients developing visual impairment, as
expressed below by a HCP.
The danger is the longer you leave a recall of course,
the more chance you have of missing that occasional
patient, so it is cost isn’t, it versus benefits really.
And also once you have missed that patient, then
trying to deal with them is more expensive. (Mark
HCP)
These concerns were echoed among some PWD who
considered that extending eye screening intervals was
considered risky as illustrated below.
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How do I know nothing is going wrong in all that
time? (David PWD, Phase 1)
PWD willingness to accept longer intervals between
screening episodes was often linked to their general
diabetes care, such as regular monitoring of blood sugar
levels, and liaising with primary care HCP and eye
screening services. So the greater the perceived risk, the
less willing PWD were to support an extended screening
interval.
Macro impact of changing screening intervals
Whilst there were many comments about the safety
of the ISDR model and its three screening intervals,
there were other more wide-ranging comments about
the macro effect of changing screening intervals. For
example, there was recognition by HCP that the
current eye screening system would not be able to
manage demands in light of the ever increasing
numbers of PWD and the related future cost of
screening
From a burden of health and competing priorities,
the NHS finance, we probably would say, there is a
recognition that this [risk-based variable-interval
screening] is probably for the increasing diabetic
population on an annual screen. (Alice HCP)
Whilst recognising the impact of increasing rates of dia-
betes on screening, there were some concerns voiced by
HCP on their job security with the introduction of
variable-interval screening.
…I think the primary thing everyone is worried
about is their jobs. That is, because again we don’t
know how many people are going to go to 24 months
and how many people are going to go to 6 months,
potentially it could you know, cut a lot of people off
our list…we are quite concerned about our jobs.
(Janine and Hannah HCP)
There were suggestions that the complexity of the vari-
able screening may serve to disadvantage particular
groups of patients. In particular, those groups who do
not engage well with services and as a result are at
higher risk of developing STDR.
It will certainly disadvantage this group that we
don’t get. We have got to find some way of getting
these young, you know, sort of 20s to 40s probably,
and a little bit beyond. Because I think you give
them an inch that you don’t need them to come for
two years – we will never see them for longer. (Sandy
& Liz HCP)
PWD also voiced similar views that risk-based variable-
interval screening should enable better targeting of
resources and would benefit patients who, for example
are difficult to engage and often do not attend for
screening, or who are at higher risk of developing STDR.
In the scenario suggested below, there is a recognition
that the NHS has finite resources and as such they need
to be allocated in a more effective manner.
We’ll have less demand on the service, therefore we’ll
be able to do a better service for other people who
need it. That’s my logic. I think it’s sensible to do ...
If the evidence shows you that it’s feasible and
worthwhile well it just makes sense to refine what
you’re doing in a way which is more productive. It
doesn’t jeopardise the patient, and it’s a better use of
resources which are limited. Makes sense, ticks the
boxes, doesn’t it? ... I’m glad it’s happening as a
process; it needs to be done. (Sid PWD, Phase 1)
Other PWD voiced a suspicion that extending intervals
between screening episodes for the majority of people
with diabetes was financially driven. But instead of being
redistributed to be more productive, the cost-savings
were aimed at restricting patients’ access to health
services.
I don’t know, if it’s like cost-effective you know,
they’re saving money. You feel like they’re saving
money to say we don’t want to see you for two years.
In your mind you think it’s about the money, other-
wise you’d be screening people every six months
anyway. (Ray PWD, Phase 1)
Of note, was that some PWD participants imagined ways
in which they could continue to have their eyes screened
on a yearly basis, such as staggering other eye appoint-
ments, as expressed below.
If they said you only need it 12 months that will do
because I have a second one in the optician anyway.
(David PWD, Phase 2)
Such comments demonstrate misunderstanding about
the rationale for different eye appointments and their
purpose. Whilst the ISDR model re-calculates a PWD
screening interval at every visit, the gaps in understand-
ing of eye screening appointments are a significant issue
in supporting PWD to manage all aspects of their dia-
betes and related care.
If I go to the optician and I can stagger those visits
so one year it’s the diabetes test and the next year
it’s the optician’s test, because the optician does look
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at the back of your eye, then that’ll be ok for me.
(Becky PWD, Phase 2)
As mentioned elsewhere in this paper, there were many
examples of confusion amongst PWDs about diabetes,
eye disease and eye screening, and, as illustrated above,
conflated health beliefs are unhelpful in managing any
changes within the eye screening service.
Discussion
Our findings show general support by PWD and HCP
for the introduction of risk-based variable-interval
screening. Key factors for our participants were the in-
creasing prevalence of diabetes and finite resources for
healthcare. Support was more clearly expressed by HCP,
likely related to a better understanding of the aims and
current pressures in screening. Our findings are reassur-
ing for policy makers and service providers who are con-
sidering introducing variable interval screening, either
stratified based on retinal grading or variable intervals
based on risk estimation. Our findings also have rele-
vance to other screening programmes with fixed inter-
vals and help to mitigate in part the concerns raised
recently in cancer screening [34]. Against these generally
supportive findings are a number of important concerns
attached to the processes around risk-based allocation
and to the screening intervals themselves, clearly
expressed by both user groups. These need to be com-
prehensively addressed to ensure successful implementa-
tion, where success can be considered to be early
detection of DR, attendance at eye screening and in-
creased understanding of the relationships between
diabetes, self-care, and eye screening.
Any changes in health services provision can be prob-
lematic for individuals and organisations and can be
amplified by routinised practice and behaviours,
systemic factors, and local discrepancies in service
provision and practice [35–37]. Implementing evidence
based practice, such as risk-based variable-interval eye
screening, is challenging and needs to address societal,
political, cultural, individual and organisational barriers.
To take into account all of these variables and their
interaction requires a sophisticated theoretical model.
Implementation science [38] is emerging as a broad the-
oretical umbrella with a range of frameworks and strat-
egies, including the BCW. As already mentioned, the
BCW identifies three sources of behaviour: capability;
opportunity; and motivation. It can then map each of
these to appropriate intervention factors for each (and
any interactions between them), with a final layer of
policy categories to firmly support an intervention.
For example, in our study, both groups of participants
expressed concerns about the potential safety of the
RCE linking to it being a more complex system, and
uncertainty around the reliability of the source data. The
BCW allows us to put these concerns into the capability
area, and to allay anxieties, there can be a mixture of in-
terventions and policy work. An intervention can be in
the form of making transparent the failsafe mechanisms
for the RCE to HCP, along with guidelines and policy by
the screening programme/Public Health England to en-
sure that data from primary care practices are embedded
with their systems. The use of champions, experts, who
are respected in their field, to present and discuss the
risk engine to other professionals, where regular updates
on the stability and accuracy of variable screening can
be fed back to clinicians, can also be a powerful inter-
vention. As we have seen from elsewhere, lessons learnt
from the lengthening of screen intervals in other screen-
ing programmes, such as breast screening in 2018 [34,
39] show that to address these concerns will require
careful explanation of the RCE and transparency about
the systems involved. There also had to be opportunities
for both HCP and PWD to refer or self-refer back into
the eye screening programme, if for example for the lat-
ter group, there have been changes in the diabetes
severity.
The introduction of the shorter interval for those at
greatest risk was widely welcomed by PWD and to a
greater extent HCP. PWD perceived the interval as re-
assuring, while recognising that it meant a higher risk of
developing sight threatening disease for them personally.
For the former group of PWD, they can be allocated to
the motivational area of the BCW, where their emotions
around reassurance will probably lead to them attending
6 monthly screening. However, for those PWD who saw
a 6month appointment as high risk, then interventions
to encourage attendance would include increased train-
ing for HCP on how to approach and engage PWD
around monitoring and preventive strategies to lessen
the chances of developing STDR. Aligned policy ap-
proaches would provide increased service provision for
these identified PWD.
The 12month interval was perceived as standard care,
but there were misunderstandings about its purpose al-
lied to an important theme of needing to disentangle
health and illness beliefs in PWD around diabetes and
eyes, and to develop a clearer understanding of the aims
of screening. There continues to be conflation and
misconstruction of these concepts along with their inter-
connectedness and purpose, as previously reported [40–
47]. The BCW can usefully place such health beliefs
(and potential health behaviours), within all three of its
components; capability, opportunity and motivational
issues. For example, a PWD who has negative emotions
about having diabetes (motivational), will need support
(interventions) from HCP, family and friends, perhaps in
the form of co-produced information, self-help groups
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and online forums to increase awareness and confidence
in their self-care. In addition, policy changes will be
needed to support increased service provision for PWD,
not just in primary care but also within communities,
such as roadshows. Furthermore, changes to the eye
screening services could potentially fracture the trust
that PWD have in the current system and in HCP, and
by default impact upon diabetes self-care. Thus, intro-
duction of any changes requires thought and consider-
ation, further complicated by the annual screening
programme having been in place for over a decade. Old
habits die hard, implementing large changes to embed-
ded clinical practice, beliefs and understanding comes
with significant challenges and any modifications will
require effort by the diabetes care team and the screen-
ing programme to explain and consolidate pertinent
information.
Potentially, the move to the 24 month interval was
controversial for PWD with mixed responses from re-
assurance to rejection. Most HCP were supportive. Both
groups expressed apprehension about the potential im-
pact on care of diabetes by PWD. The BCW suggests
that behaviours related to opportunity, such as feeling
rejection, is outside of an individual’s control. To allay
and soothe such high emotions, which could well lead to
non-attendance at screening, can be managed by persua-
sive relationships (interventions) between a HCP and
PWD, where clear explanations are provided that are
tailored to the PWD. These conversations can also be
backed up with good communication and marketing
policy by Public Health England.
Our qualitative study ran in parallel with the ISDR
RCT which has shown that risk-based variable-interval
screening is safe and effective when compared to annual
screening (manuscript under review). Cost-effectiveness
is greatly improved allowing resources to be reallocated,
including for hard to reach and vulnerable groups. 22%
of people declined to participate in the RCT study expli-
citly stating that they wished to remain in annual screen-
ing or did not want a change of interval, this is further
evidence of a level of resistance to changing intervals.
However dropout in the 2265 PWD randomised to
variable interval screening was very low.
Strengths and limitations
Our PWD participants represented a broad range of in-
dividuals with diabetes giving a variety of views from
their experiences. Our HCP informants were multidis-
ciplinary and with a range of ages and experience. This
affords a breadth of experiences and views, enhanced by
our purposive sampling approach and co-produced topic
guide. The study was informed by our PI group who
commented on all aspects of the research process and
were able to inform the content of the topic guides
based on their own experiences of diabetes and eye
screening.
Our participants may have been motivated to take part
in interviews as a way of expressing their views on par-
ticular topics related to diabetes care, or gaining social
contact. PWD participants in Phase 1 were not the same
individuals as in Phase 2.
Conclusions
Extending intervals and introducing a fully personalised
approach is gathering momentum in screening for
diabetic retinopathy, and in other areas of disease
prevention in the UK.
Our qualitative work sheds new light on the issues
around implementing risk-based, variable-interval, and
stratified screening using the BCW, with PWD and HCP
generally supportive. For successful implementation, a
range of issues must be addressed: interpretable and
clear safeguards for individual PWD are required against
increasing non-attendance, loss of diabetes control and
system failures; alternative referral pathways are needed
for those lost to follow-up or whose risk factors change
substantially over longer intervals; and, for risk calcula-
tion systems, reliable monitoring and clear communica-
tion is necessary. Utilising the frameworks for changing
health services provision in the BCW is likely to improve
implementation.
Abbreviations
DR: Diabetic retinopathy; HCP: Health care professionals; PI: Public
involvement; PWD: Person with diabetes; RCE: Risk calculation engine;
STDR: Sight threatening diabetic retinopathy
Acknowledgements
Participants for their help. Research teams from North West Coast and
Clinical Eye Research Centre who helped to identify participants. ISDR study
group.
Authors’ contributions
All authors met ICMJE requirements, making (1) substantial contributions to
conception and design, acquisition of data, or analysis and interpretation of
data; (2) drafting the article or revising it critically for important intellectual
content; and (3) giving final approval of the version to be published. PB, CT,
PC and SPH wrote drafts of the manuscript; ED provided PPI review; MG is
responsible for the integrity of the work as a whole. PB is guarantor for the
data.
Funding
This study/project is funded by the National Institute for Health Research
(NIHR) [Programme Grants for Applied Research (RP-PG-1210-1201)]. The
views expressed are those of the authors and not necessarily those of the
NIHR or the Department of Health and Social Care. MG is part funded by
NIHR Applied Research Collaboration North West Coast (NIHR ARC NWC).
Availability of data and materials
The data generated and analysed during this study is available from the
corresponding author on reasonable request.
Ethics approval and consent to participate
Ethical approval was given by NHS North West, Preston Research Ethics
Committee. The two phases of the study were conducted under the
following research ethics committee approvals: 13/NW/0287 and 16/NW/
0061. All participants provided signed informed consent.
Byrne et al. BMC Public Health          (2020) 20:881 Page 10 of 12
Consent for publication
All quotes are anonymised, no personal information was included.
Competing interests
The author's declare that they have no competing interests.
Author details
1Institute of Population Health, University of Liverpool, Liverpool, UK. 2Faculty
of Health and Wellbeing, University of Central Lancashire, Liverpool, UK.
3ISDR Public Involvement Group, University of Liverpool, Liverpool, UK. 4Eye
and Vision Science, University of Liverpool and St. Paul’s Eye Unit, Royal
Liverpool University Hospital, Preston, UK.
Received: 24 September 2019 Accepted: 24 May 2020
References
1. https://www.diabetes.org.uk/professionals/position-statements-reports/
statistics. Accessed 22 Aug 2019.
2. https://www.diabetes.org.uk/about_us/news/new-stats-people-living-with-
diabetes. Accessed 22 Aug 2019.
3. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 11
Mar 2019.
4. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness
certifications in England and Wales in working age adults (16-64 years),
1999-2000 with 2009-2010. BMJ Open. 2014;4:e004015.
5. Agardh E, Tabayat-Khani P. Adopting 3-year screening intervals for sight-
threatening retinal vascular lesions in type 2 diabetic subjects without
retinopathy. Diabetes Care. 2011;34:1–2.
6. Echouffo-Tcheugui JB, Ali MK, Roglic G, Hayward RA, Narayan KM. Screening
intervals for diabetic retinopathy and incidence of visual loss: a systematic
review. Diabet Med. 2013;30(11):1272–92.
7. Grauslund J, Andersen N, Andresen J, et al. Evidence-based Danish
guidelines for screening of diabetic retinopathy. Acta Ophthalmol. 2018;96:
763–9.
8. Looker HC, Nyangoma SO, Cromie DT, et al. Predicted impact of extending
the screening interval for diabetic retinopathy: the Scottish diabetic
retinopathy screening programme. Diabetologia. 2013;56:1716–25.
9. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M,
Clarke A. Extending the diabetic retinopathy screening interval beyond 1
year: systematic review. Br J Ophthalmol. 2016;100:105–14.
10. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight
threatening retinopathy in type 2 diabetes in a systematic screening
programme. Lancet. 2003;361:195–200.
11. Basu S, Sussman JB, Berkowitz SA, et al. Validation of risk equations for
complications of type 2 diabetes (RECODe) using individual participant data
from diverse longitudinal cohorts in the US. Diabetes Care. 2018;41:586–95.
12. Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, et al.
Progression of diabetes retinal status within community screening
programs and potential implications for screening intervals. Diabetes Care.
2015;38:488–94.
13. Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes
without retinopathy: 10-year experience. Br J Ophthalmol. 2007;91:1599–601.
14. Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and
benefit-to-harm ratio of risk-stratified screening for breast cancer a life-table
model. JAMA Oncol. 2018;4(11):1504–10.
15. Eleuteri A, Fisher AC, Broadbent DM, Garcia-Finana M, Cheyne CP, Wang A,
Stratton IM, Gabbay M, Seddon D, Harding SP. Individualised variable-
interval risk-based screening for sight-threatening diabetic retinopathy: the
Liverpool risk calculation engine. Diabetalogica. 2017;60(11):2174–82.
16. Aspelund T, Thornórisdóttir O, Olafsdottir E, et al. Individual risk assessment
and information technology to optimise screening frequency for diabetic
retinopathy. Diabetologia. 2011;54:2525–32.
17. van der Heijden AA, Walraven I, et al. Validation of a model to estimate
personalised screening frequency to monitor diabetic retinopathy.
Diabetologia. 2014;57:1332–8.
18. van der Heyden AAWA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM.
Prediction of coronary heart disease risk in a general, pre-diabetic and
diabetic population during 10 years of follow-up: accuracy of the
Framingham SCORE and UKDPS risk functions, the Hoorn study. Diabetes
Care. 2009;32(11):2094–8.
19. Becker M. The health belief model and personal health behavior. Health
Educ Monogr. 1974;2:324–508.
20. Prochaska JO, DiCelemente CC. Stages and processes of self-change of
smoking: toward an integrativemodel of change. J Consult Clin Psychol.
1983;51:390–5.
21. Marlatt G, Gordon J. Relapse prevention: a self-control strategy for the
maintenance of behavior change. New York: Guilford Press; 1984.
22. Michie S, van Stralen MM, West R. The behaviour change wheel: a new
method for characterising and designing behaviour change interventions.
Implement Sci. 2011;6:42.
23. Rubin SE, Davis K, McKee MD. New York City physicians’ views of providing
long-acting reversible contraception to adolescents. Ann Fam Med. 2013;
11(2):130–6.
24. Bonner C, Jansen J, Newell BR, Irwig L, Glasziou P, Doust J, McCaffery K. I
don’t believe it, but I’d better do something about it: patient experiences of
online heart age risk calculators. J Med Internet Res. 2014;16(5):e120. https://
doi.org/10.2196/jmir.3190.
25. Broadbent DM, Sampson CJ, Wang A, Howard L, Williams AE, Howlin SU,
Appelbe D, Moitt T, Cheyne CP, Rahni MM, Kelly J, Collins J, García-Fiñana
M, Stratton IM, James M, Harding SP, ISDR Study Group. Individualised
screening for diabetic retinopathy: the ISDR study-rationale, design and
methodology for a randomised controlled trial comparing annual and
individualised risk-based variable-interval screening. BMJ Open. 2019;179(6):
e025788.
26. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M.
Developing and evaluating complex interventions: the new Medical
Research Council guidance. Br Med J. 2008;337:a1655.
27. Flick U. An introduction to qualitative research. 6th ed. London: Sage
Publications; 2018.
28. Galletta A. Mastering the semi-structured interview and beyond. New York:
NYU Press; 2013.
29. Coffey A, Atkinson P. Making sense of qualitative data: complementary
research strategies. London: Sage; 2006.
30. Silverman D. Interpreting qualitative data. 4th ed. London: Sage; 2011.
31. Mason J. Qualitative researching. 3rd ed. London: Sage; 2017.
32. Smith J, Firth J. Qualitative data analysis: application of the framework
approach. Nurse Res. 2011;18(2):52–62.
33. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework
method for the analysis of qualitative data in multi-disciplinary health
research. BMC Med Res Methodol. 2013;13:117.
34. National Health Executive. Backlog of 150,000 cervical screenings revealed
as all major health screenings failing to hit targets http://www.
nationalhealthexecutive.com/News/backlog-of-150000-cervical-screenings-
revealed-as-all-major-health-screenings-failing-to-hit-targets-/220549.
Accessed 9 May 2019.
35. Coleman T. Do financial incentives for delivering health promotion
counselling work? Analysis of smoking cessation activities stimulated by the
quality and outcomes framework. BMC Public Health. 2010;10:167. https://
doi.org/10.1186/1471-2458-10-167.
36. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L. Changing
provider behavior: an overview of systematic reviews of interventions. Med
Care. 2001;39(8 Suppl 2):II2–45.
37. Summerbell C, Waters E, Edmunds L, Kelly S, Brown T, Campbell K.
Interventions for preventing obesity in children. Cochrane Database Syst
Rev. 2005:3(5):CD001871–3.
38. Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction
to implementation science. for the non-specialist. Psychology. 2015;3:32.
39. Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen THH, et al. Absolute
numbers of lives saved and overdiagnosis in breast cancer screening, from
a randomized trial and from the breast screening programme in England. J
Med Screen. 2010;17:25–30.
40. Lewis K, Patel D, Yorston D, Charteris D. A qualitative study in the United
Kingdom of factors influencing attendance by PWD diabetes at ophthalmic
outpatient clinics. Ophthalmic Epidemiol. 2007;14:375–80.
41. Applebee E (2012). The barriers and enablers that affect access to primary
and secondary eye care services — Bradford site report. RNIB report: RNIB/
CEP/IR/Bradford/01.
42. Zoega GM, Gunnarsdottir T, Bjornsdottir S, et al. Screening compliance and
visual outcome in diabetes. Acta Ophthalmol Scand. 2005;83(6):687–90.
43. Gray RH, Blades C, Jobson T. Screening clinic non-attendance and the risk of
sight threatening retinopathy. Euro J Opthalmol. 2019;19(3):510.
Byrne et al. BMC Public Health          (2020) 20:881 Page 11 of 12
44. Strutton R, Du Chemin A, Stratton IM, Forster AS. System-level and patient-
level explanations for non-attendance at diabetic retinopathy screening in
Sutton and Merton (London, UK): a qualitative analysis of a service
evaluation. BMJ Open. 2016;6(5):e010952.
45. Hurrell DD, Donohue S. The barriers and enablers that affect access to
primary and secondary eye care services - Glasgow site report. Glasgow:
RNIB; 2012.
46. Hipwell AE, Sturt J, Lindenmeyer A, Stratton I, Gadsby R, O’Hare P, et al.
Attitudes, access and anguish: a qualitative interview study of staff and
patients’ experiences of diabetic retinopathy screening. BMJ Open. 2014;4:
e005498.
47. Moss SE, Klein R, Klein BE. Factors associated with having eye examinations
in persons with diabetes. Arch Fam Med. 1995;4:529–34.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Byrne et al. BMC Public Health          (2020) 20:881 Page 12 of 12
